Alzheimer's Disease & Dementia
An Introduction to Alzheimer's Disease & Dementia
Major advances in the understanding of the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia, have occurred over recent years, but the need for truly disease-modifying therapies remains. Novel pharmacotherapy strategies under investigation include the repurposing of medications used to treat non-AD illnesses and multi-target-directed ligands, offering promise in this challenging treatment landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Alzheimer's Disease & Dementia Content
Recent advances in neuroimaging technologies and future directions for early assessment and monitoring in Alzheimer’s disease
Watch behavioural neurologist and neuroscientist Dr Brad Dickerson discuss recent advances and future directions in neuroimaging technologies in Alzheimer’s disease.
- Recognize the importance of early and accurate diagnosis in AD and consider evidence-based guidelines supporting the use of neuroimaging techniques to confirm the diagnosis
- Review recent advances in neuroimaging techniques and their practical application in the current and future management of AD
- Discuss the use of neuroimaging biomarkers for patient diagnosis, selection and monitoring in clinical trials and in the future management of AD
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Gregory Branigan, AAN 2021: Impact of Estrogen Therapies on Alzheimer’s Disease Pathways
We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways. The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: What […]
Jeffrey Cummings, AAN 2021: BAN2401 Effects On Brain Amyloid And ARIA-E Findings
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our Editorial Board Members, to discuss BAN2401’s use in early stage Alzheimer’s Disease, and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings […]
Jeffrey Cummings, AAN 2021: Phase 2b Study of BAN2401 in subjects with Early Alzheimer’s Disease
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our valued Editorial Board Members, to discuss the open-label extension of the Phase 2b Study (BAN2401-G000-201) in subjects with early Alzheimer’s Disease. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of […]
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Yona Levites, AD/PD 2021: Immunotherapeutic Approaches in Alzheimer’s Disease (Part 1)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
Yona Levites, AD/PD 2021: Immunotherapeutic approaches in Alzheimer’s Disease (Part 2)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA ) to discuss her phase 1 study investigating the scFv-CD protein as a framework for identifying an optimized immunotherapy for Alzheimer’s Disease, and potentially other neurodegenerative disorders. Part 1 of the discussion can […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!